title: Ketoconazole retains activity in patients with docetaxel-refractory prostate cancer.
authors.forename: M D
authors.initials: MD
authors.lastname: Galsky
authors.forename: K
authors.initials: K
authors.lastname: Simon
authors.forename: G
authors.initials: G
authors.lastname: Sonpavde
authors.forename: T E
authors.initials: TE
authors.lastname: Hutson
authors.forename: M
authors.initials: M
authors.lastname: Fleming
authors.forename: G V
authors.initials: GV
authors.lastname: Kondagunta
authors.forename: W
authors.initials: W
authors.lastname: Berry
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000077143:Docetaxel; D019008:Drug Resistance, Neoplasm; D006801:Humans; D007654:Ketoconazole / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D012189:Retrospective Studies; D043823:Taxoids / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D043823:Taxoids; D000077143:Docetaxel; D017430:Prostate-Specific Antigen; D007654:Ketoconazole